Related Experiment Video
Updated: Nov 12, 2025

Oligopeptide Competition Assay for Phosphorylation Site Determination
Published on: May 18, 2017
AMPK-dependent phosphorylation is required for transcriptional activation of TFEB and TFE3
Mathieu Paquette1,2, Leeanna El-Houjeiri1,2, Linda C Zirden1,2
1Goodman Cancer Research Center, McGill University, Montréal, Québec, Canada.
Abstract:
Increased macroautophagy/autophagy and lysosomal activity promote tumor growth, survival and chemo-resistance. During acute starvation, autophagy is rapidly engaged by AMPK (AMP-activated protein kinase) activation and MTOR (mechanistic target of rapamycin kinase) complex 1 (MTORC1) inhibition to maintain energy homeostasis and cell survival. TFEB (transcription factor E3) and TFE3 (transcription factor binding to IGHM enhancer 3) are master transcriptional regulators of autophagy and lysosomal activity and their cytoplasm/nuclear shuttling is controlled by MTORC1-dependent multisite phosphorylation. However, it is not known whether and how the transcriptional activity of TFEB or TFE3 is regulated. We show that AMPK mediates phosphorylation of TFEB and TFE3 on three serine residues, leading to TFEB and TFE3 transcriptional activity upon nutrient starvation, FLCN (folliculin) depletion and pharmacological manipulation of MTORC1 or AMPK. Collectively, we show that MTORC1 specifically controls TFEB and TFE3 cytosolic retention, whereas AMPK is essential for TFEB and TFE3 transcriptional activity. This dual and opposing regulation of TFEB and TFE3 by MTORC1 and AMPK is reminiscent of the regulation of another critical regulator of autophagy, ULK1 (unc-51 like autophagy activating kinase 1). Surprisingly, we show that chemoresistance is mediated by AMPK-dependent activation of TFEB, which is abolished by pharmacological inhibition of AMPK or mutation of serine 466, 467 and 469 to alanine residues within TFEB. Altogether, we show that AMPK is a key regulator of TFEB and TFE3 transcriptional activity, and we validate AMPK as a promising target in cancer therapy to evade chemotherapeutic resistance.Abbreviations: ACACA: acetyl-CoA carboxylase alpha; ACTB: actin beta; AICAR: 5-aminoimidazole-4-carboxamide ribonucleotide; AMPK: AMP-activated protein kinase; AMPKi: AMPK inhibitor, SBI-0206965; CA: constitutively active; CARM1: coactivator-associated arginine methyltransferase 1; CFP: cyan fluorescent protein; CLEAR: coordinated lysosomal expression and regulation; DKO: double knock-out; DMEM: Dulbecco's modified Eagle's medium; DMSO: dimethyl sulfoxide; DQ-BSA: self-quenched BODIPY® dye conjugates of bovine serum albumin; EBSS: Earle's balanced salt solution; FLCN: folliculin; GFP: green fluorescent protein; GST: glutathione S-transferases; HD: Huntington disease; HTT: huntingtin; KO: knock-out; LAMP1: lysosomal associated membrane protein 1; MEF: mouse embryonic fibroblasts; MITF: melanocyte inducing transcription factor; MTORC1: MTOR complex 1; PolyQ: polyglutamine; RPS6: ribosomal protein S6; RT-qPCR: reverse transcription quantitative polymerase chain reaction; TCL: total cell lysates; TFE3: transcription factor binding to IGHM enhancer 3; TFEB: transcription factor EB; TKO: triple knock-out; ULK1: unc-51 like autophagy activating kinase 1.
Insights
AMP-activated protein kinase (AMPK) activates transcription factors TFEB and TFE3, controlling autophagy and lysosomal activity. This AMPK-mediated activation is crucial for chemoresistance and presents a potential therapeutic target in cancer.
Area of Science:
- Cellular Biology
- Molecular Biology
- Cancer Research
Background:
- Autophagy and lysosomal activity are critical for tumor growth, survival, and chemoresistance.
- AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin complex 1 (MTORC1) regulate autophagy during starvation.
- Transcription factors TFEB and TFE3 are master regulators of autophagy and lysosomal genes, with their activity controlled by MTORC1-dependent phosphorylation.
Purpose of the Study:
- To investigate the regulation of TFEB and TFE3 transcriptional activity.
- To elucidate the role of AMPK in TFEB and TFE3 activation.
- To determine the involvement of AMPK-TFEB signaling in cancer chemoresistance.
Main Methods:
- Phosphorylation site analysis of TFEB and TFE3.
- Nutrient starvation and pharmacological manipulation of AMPK and MTORC1.
- Gene expression analysis using RT-qPCR.
- Assessment of chemoresistance in cancer cells.
- Site-directed mutagenesis of TFEB phosphorylation sites.
Main Results:
- AMPK mediates phosphorylation of TFEB and TFE3 on specific serine residues, enhancing their transcriptional activity.
- MTORC1 promotes TFEB and TFE3 cytosolic retention, while AMPK promotes their transcriptional activity.
- AMPK-dependent activation of TFEB is essential for chemoresistance.
- Inhibition of AMPK or mutation of key serine residues in TFEB abolishes chemoresistance.
Conclusions:
- AMPK is a key regulator of TFEB and TFE3 transcriptional activity, opposing MTORC1's inhibitory role.
- AMPK-driven TFEB activation contributes to cancer cell chemoresistance.
- Targeting AMPK may represent a novel therapeutic strategy to overcome chemotherapeutic resistance in cancer.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Cell Specific Gene Expression
MAPK Signaling Cascades
cAMP-dependent Protein Kinase Pathways
Master Transcription Regulators
TGF - β Signaling Pathway

